Drug delivery device, method of manufacture, and method of use

US11266777B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Scott R. Gibson · San Fernando, US
• Sheldon Moberg · Thousand Oaks, US
• Basel Hasan Taha · Westlake Village, US
• Margaux Frances Boyaval · Newbury Park, US
• Mark A. Destefano · Collegeville, US
• John C. Love · Vista, US
• Ian B. Hanson · San Fernando, US
• Paul F. Bente, IV · Wayne, US
• Matthew J. Clemente · Downingtown, US
• Rajan Ramaswamy · San Diego, US
• Daniel Shawn Codd · Escondido, US
• Scott Beaver · San Marcos, US
• Kevin Bokelman · Village of La Jolla, US
• Sean M. O'Connor · San Diego, US
• Robert Decker · Dillsburg, US
• Gautam N. Shetty · Pikesville, US
• Ryan Agard · Royersford, US
• Nicholas J. Ciccarelli · Philadelphia, US
• Daniel Davenport · Collegeville, US

Key dates

• Filing date: Feb 13, 2017
• Grant date: Mar 8, 2022
• Expiry date: Jun 2, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61M2205/35
• WIPO field: Medical technology
• WIPO sector: Instruments

Abstract

Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.